NICE recommends Erbitux in combination with chemotherapy for the treatment of head and neck cancer
Decision secures access to Erbitux for new patients in England with oral cavity tumours.
Merck has announced that the National Institute for Health and Care Excellence (NICE) for England has issued a positive Final Appraisal Determination (FAD) recommending the routine National Health Service (NHS) use of Erbitux (cetuximab) in combination with platinum-based chemotherapy as a first-line therapy for the treatment of patients with recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the oral cavity. NICE’s decision confirms the positive benefit Erbitux can have on the survival of patients in this setting. Erbitux is already established and reimbursed as an effective therapy for different stages of SCCHN across many countries worldwide.
“This announcement secures continued access to Erbitux for patients in England who have R/M SCCHN with oral cavity tumors – a positive step forward as the only other available treatment option is platinum-based chemotherapy. Our ultimate goal is to secure access to Erbitux for all patients living with R/M SCCHN,” said Maya MartinezDavis, Global Head of Oncology Franchise for Merck’s biopharma business. “Today’s recommendation marks another important achievement in our commitment to ensuring that patients worldwide have access to optimal treatments.”
For patients with R/M SCCHN, Erbitux has been available in England through the Cancer Drugs Fund (CDF) since 2010. This was in line with the current European Society for Medical Oncology and the US National Comprehensive Cancer Network clinical practice guidelines. Both guidelines recommend Erbitux in combination with platinum-based chemotherapy, followed by Erbitux maintenance monotherapy to disease progression, as the first line standard of care for patients with R/M SCCHN, regardless of tumor location.
In 2016, a new approach to the appraisal and funding of cancer drugs in England came into place and all drugs previously funded by the CDF had to be reassessed by NICE. The reassessment reviews if the treatments bring sufficient clinical benefit to patients to be a cost-effective use of NHS resources. Erbitux has obtained marketing authorization in over 90 countries worldwide. To date, more than 259,000 patients with SCCHN have been treated with Erbitux.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News Pharmapack 2024 - From the Floor
Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delive... -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most. -
News CPHI Barcelona 2023: Loading Potential – Artificial Intelligence for Pharma Manufacturing
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News CPHI Podcast Series: Start-ups take centre stage at CPHI Barcelona
The first episode of the CPHI Podcast Series since we attended CPHI Barcelona in October covers the Start-up market at the event, with expert Matthew Wise joining Editor Lucy Chard to discuss the event.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance